孕妇乙型肝炎病毒感染筛查与管理*

doi:10.3969/j.issn.1672-5069.2019.01.004

Abstract

Wang Qi, Xie Wen.. Screening and management of pregnant women with hepatitis B viral infection[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 9-12.

[1] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年版). 实用肝脏病杂志. 2016,19(3): 389-400.
[2] 刘会敏,相元翠,粟浩然,等.《2017年加拿大妇产科医师协会临床实践指南:乙型肝炎与妊娠》摘译. 临床肝胆病杂志. 2017,32(9):1663-1667.
[3] 中华医学会肝病学分会. 感染乙型肝炎病毒的育龄女性临床管理共识. 中华肝脏病杂志,2018,32(3):204-208.
[4] 中国肝炎防治基金会,中华医学会感染病学分会,中华医学会肝病学分会. 乙型肝炎母婴阻断临床管理流程. 中华肝脏病杂志. 2017,31(4):254-256.
[5] 窦晓光. 育龄期妇女及孕妇抗乙型肝炎病毒治疗策略. 中华肝脏病杂志,2015,29(11):801-802.
[6] Lampertico P,Agarwal K,Berg T,et al.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol,2017,67(2):370-398.
[7] Pan CQ,Han GR,Jiang HX,et al.Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol,2012,10(5):520-526.
[8] Han L,Zhang HW,Xie JX,et al.A Meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol,2011,17(38):4321-4333.
[9] Liu MH,Sheng YJ,Liu JY,et al.Efficacy of telbivudine on interruption of hepatitis B virus vertical transmission:a Meta-analysis. Ann Saudi Med,2013,33(2):169-176.
[10] Greenup AJ,Tan PK,Nguyen V,et al.Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol,2014,61(3):502-507.
[11] Pan CQ,Duan Z,Dai E,et al.Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med,2016,374(24):2324-2334.
[12] Bruni R,Taliani G,Ciccaglione AR.Antiviral treatment of HBV positive pregnant women:an additional tool to reduce perinatal transmission. Pathog Glob Health,2016,110(7-8):275-276.
[13] Terrault NA,Lok A S,Mcmahon BJ,et al.Update on prevention,diagnosis,and treatment and of chronic hepatitis B:AASLD 2018 hepatitis B guidance. Hepatology,2018,67(4):312-316.
[14] Organization of World Health. Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection. World Health Organization,2015.
[15] Terrault NA,Bzowej NH,Chang KM,et al.AASLD guidelines for treatment of chronic hepatitis B. Hepatology,2015,63(1): 261-283.
[16] Jourdain G,Ngogianghuong N,Harrison L,et al.Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med,2018,378(10):911.
[17] 万谟彬,窦晓光. 2013年版英国《儿童、青年和成人慢性乙型肝炎诊断和管理指南》解读. 中华肝脏病杂志,2014,22(8):561-566.
[18] Yi W,Pan CQ,Hao J,et al.Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers. J Hepatol,2014,60(3):523-529.
[19] 周乙华,胡娅莉. 我国预防乙型肝炎母婴传播的进展和亟待研究的问题. 中华围产医学杂志,2018,15(8):505-509.

Screening and management of pregnant women with hepatitis B viral infection

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Tang Renyi, Hu Qunfeng, Peng Liqing.. Changes of serum lipids, liver function tests and estrogen levels in patients with intrahepatic cholestasis of pregnancy and its clinical significance [J]. Journal of Practical Hepatology, 2019, 22(6): 860-863.
[8]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[9]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[10]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[11]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[12]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[13]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[14]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[15]	Hu Qunfeng, Yang Li. Pregnancy outcomes in 112 patients with liver injuries during gestation periods [J]. Journal of Practical Hepatology, 2019, 22(5): 664-667.